Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that the acquisition has closed, the pharmaphorum podcast welcomes Arnaub Chatterjee, president and general manager of life sciences at Datavant, to discuss what that integration will look like -- and what the implications are for the pharma industry. Chatterjee discusses how the acquisition came about and what the strategic fit looks like between the two organisations, as well as how they will complement each other going forward. While the focus is on the news and what it means, Chatterjee and host Jonah Comstock also delve into some larger topics around real-world data in life sciences – how it’s being used, how regulators are responding to it, some of the biggest roadblocks holding the space back, and what the competitive landscape looks like. And Chatterjee shares his vision for what the future of data discovery, linkage, and analytics in life sciences could look like. Tune in for the full discussion on this exciting industry development.